Funder
National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology
Publisher
Springer Science and Business Media LLC
Subject
Endocrine and Autonomic Systems,Endocrinology,Endocrinology, Diabetes and Metabolism
Reference38 articles.
1. FDA approves first treatment for thyroid eye disease.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease
. Accessed 2 July 2020.
2. Smith TJ, et al. Teprotumumab for thyroid-associated Ophthalmopathy. N Engl J Med. 2017;376:1748–61.
3. Douglas RS, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341–52.
4. Jain D, Mor S, Aggarwal HK, Chhabra P, Jain P. Thyroid association Ophthalmopathy in Hashimoto’s thyroiditis: a case report. Maedica. 2017;12:65–7.
5. Wiersinga WM, Bartalena L. Epidemiology and prevention of graves’ ophthalmopathy. Thyroid Off J Am Thyroid Assoc. 2002;12:855–60.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献